ISB News

Dr. Lee Hood Writes ‘Second Opinion’ Columns for Los Angeles Times

ISB Co-founder, Chief Strategy Officer and Professor Dr. Lee Hood is credited with coining the term “systems biology,” and has been a longtime advocate of P4 medicine (predictive, preventive, personalized and participatory).

Now, Hood has been selected by the Los Angeles Times to share his insights in a new weekly op-ed column, called Second Opinion.

The column “aims to engage cutting-edge debates about the unprecedented global challenges that our society faces” and “will feature contributions from thought leaders, scientists, diplomats, humanitarians, artists, economists, and other experts who will offer their insights into these challenges, in an effort to identify solutions and actions to solve them,” said Dr. Patrick Soon-Shiong, executive chairman of the L.A. Times, in an article announcing the weekly column.

Hood has penned two columns, and more are in the works. The Second Opinion columns are published in print in Sunday Los Angeles Times newspapers and appear on latimes.com. They are also syndicated by Yahoo News and many other outlets. Prior to the launch of Second Opinion, Hood and author Matthew LaPlante wrote an op-ed for the Los Angeles Times.

Dr. Hood’s Columns:

 

Claire Reid / Los Angeles Times; Getty Images, Unsplash

Image Courtesy Claire Reid / Los Angeles Times; Getty Images, Unsplash

Op-Ed: The key to treating Alzheimer’s disease may not be a drug
June 30, 2021

Read more

Los Angeles Times Image

Image courtesy Los Angeles Times / Nicole Vas

Second Opinion: How long haul COVID could offer clues for treating other puzzling illnesses
April 18, 2021

Read more

Los Angeles Times Image

Image courtesy Los Angeles Times / Science Photo Library / Associated Press

Second Opinion: Getting past disease to the science of wellness
March 21, 2021

Read more

Los Angeles Times Image

Image courtesy Los Angeles Times / Associated Press

Op-Ed: How science education can stave off demagogues
January 24, 2021

Read more

Recent Articles

  • In First-of-Its-Kind Trial, Scientists Use CRISPR to Treat Cancer

    Scientists for the first time have used CRISPR to substitute a gene to treat patients with cancer. The remarkable findings were published in the journal Nature and presented at the Society for Immunotherapy of Cancer (SITC) 2022.

  • The Gut Microbiome’s Supersized Role In Shaping Our Metabolome

    ISB researchers have shown which blood metabolites are associated with the gut microbiome, genetics, or the interplay between both. Their findings, published in the journal Nature Metabolism, have promising implications for guiding targeted therapies designed to alter the composition of the blood metabolome to improve human health.

  • Spotlight on ISB Education graphic

    2022-23 School Year ISB Education Highlights

    From planning, creating and executing workshops for educators to forging new relationships to elevate students, the ISB Education team has been in high gear. Each month throughout the 2022-2023 academic year, we will highlight some of the top projects the team is working on.